NASDAQ$EPIX
Essa Pharma Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
ESSA Pharma reported financial results for the fiscal fourth quarter and year ended September 30, 2020.
ESSA Pharma reported its financial results for the fiscal year ended September 30, 2020. The company had cash reserves and short-term investments of $78,332,100 as of September 30, 2020, which includes $48.9 million raised in a public offering in July.
- Made significant progress towards the development of EPI-7386.
- Initiated a Phase 1 monotherapy dose escalation clinical study with EPI-7386 in July.
- Well-positioned financially to advance the development of EPI-7386 with $48.9 million raised in a public offering.
- Planning to initiate one or more combination studies with approved anti-androgen treatments.
Headline financials
Revenue & EPS history
Essa Pharma · Revenue · Quarterly
$0
Forward guidance
The company is focused on advancing the clinical development of EPI-7386 and initiating combination studies with approved anti-androgen treatments.
Tailwinds
- Advancing the development of EPI-7386 in the current Phase 1 study
- Initiating one or more combination studies with approved anti-androgen treatments
- Obtaining positive results of clinical trials
- Obtaining necessary regulatory approvals
- Favorable general business, market and economic conditions
Headwinds
- Inaccuracy of ESSA’s financial projections
- Failure to obtain positive results of clinical trials
- Failure to obtain necessary regulatory approvals
- Unfavorable general business, market and economic conditions
- Risks and uncertainties related to medical, scientific, business, economic, competitive, political and social factors
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports
-0.3%
Avg return
Earnings day
+1.1%
Avg return
5 days after
-3.2%
Avg return
30 days after
39%
13 / 33 earnings
Positive
+46.0%
Q1 2021
Best reaction
-34.9%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +0.0% | +0.0% | -89.5% | |
| Q2 2025 | +1.2% | -1.8% | -1.2% | |
| Q1 2025 | -3.0% | +3.6% | -2.4% | |
| Q4 2024 | -1.2% | -1.8% | +7.4% | |
| Q3 2024 | -5.5% | -2.6% | +22.9% | |
| Q2 2024 | +4.6% | +4.9% | -21.3% | |
| Q1 2024 | +2.5% | -5.4% | -10.0% | |
| Q4 2023 | +3.2% | +16.4% | +58.7% | |
| Q3 2023 | -2.8% | -4.5% | -5.6% | |
| Q2 2023 | -4.1% | +2.7% | +8.6% | |
| Q1 2023 | +2.1% | +0.3% | -2.4% | |
| Q4 2022 | -6.9% | — | — | |
| Q3 2022 | +3.1% | — | — | |
| Q2 2022 | +5.4% | — | — | |
| Q1 2022 | +1.4% | — | — | |
| Q4 2021 | +0.6% | — | — | |
| Q3 2021 | -34.9% | — | — | |
| Q2 2021 | -1.8% | — | — | |
| Q1 2021 | +46.0% | — | — | |
| Q4 2020 | +8.6% | — | — | |
| Q1 2020 | +0.0% | — | — | |
| Q4 2019 | -0.2% | — | — | |
| Q1 2019 | +3.2% | — | — | |
| Q2 2019 | -8.7% | — | — | |
| Q4 2018 | -2.4% | — | — | |
| Q1 2018 | -8.1% | — | — | |
| Q4 2016 | +0.0% | — | — | |
| Q3 2016 | +0.0% | — | — | |
| Q2 2016 | -5.8% | — | — | |
| Q1 2016 | +2.2% | — | — | |
| Q4 2015 | -8.2% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro